{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:26:36Z","timestamp":1792808796076,"version":"4.5.0"},"reference-count":31,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>The relationship between the genomic profile and prognosis of advanced thyroid carcinoma requiring drug therapy has not been reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the treatment period and overall survival time for each genetic alteration in advanced thyroid carcinoma that requires drug therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective observational study using a national database in Japan, which included 552 cases of thyroid carcinoma out of 53 543 patients in the database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The database included anaplastic thyroid carcinoma (23.6%), poorly differentiated thyroid carcinoma (10.0%), and differentiated thyroid carcinoma (66.4%). The most common genetic abnormalities were TERT promoter (66.3%), BRAF (56.7%), and TP53 (32.2%). The typical driver genes were BRAF V600E (55.0%), RAS (18.5%), RET fusion (4.7%), NTRK fusion (1.6%), and ALK fusion (0.4%). The most common regimen was lenvatinib, and the time to treatment failure was not different despite the presence of BRAF or RAS mutations. In differentiated thyroid carcinoma and poorly differentiated thyroid carcinoma, TP53 alterations independently predicted worse overall survival (hazard ratio = 2.205, 95% confidence interval: 1.135-4.283). In anaplastic thyroid carcinoma, no genetic alterations were associated with overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Genetic abnormalities with treatment options were found in 62.7% of advanced thyroid carcinomas. TP53 abnormality was an independent poor prognostic factor for overall survival in differentiated thyroid carcinoma. The time to treatment failure for lenvatinib was not different based on genetic profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgae271","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T21:00:18Z","timestamp":1713301218000},"page":"2784-2792","source":"Crossref","is-referenced-by-count":32,"title":["Genomic Landscape and Clinical Features of Advanced Thyroid Carcinoma: A National Database Study in Japan"],"prefix":"10.1210","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2977-4419","authenticated-orcid":false,"given":"Soji","family":"Toda","sequence":"first","affiliation":[{"name":"Department of Endocrine Surgery, Kanagawa Cancer Center , Kanagawa 241-8515 ,","place":["Japan"]},{"name":"Department of Breast and Thyroid Surgery, Yokohama City University Medical Center , Kanagawa 232-0024 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiko","family":"Hiroshima","sequence":"additional","affiliation":[{"name":"Department of Cancer Genome Medicine, Kanagawa Cancer Center , Kanagawa 241-8515 ,","place":["Japan"]},{"name":"Research Institute Division of Advanced Cancer Therapeutics, Kanagawa Cancer Center Research Institute , Kanagawa 241-8515 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9724-8525","authenticated-orcid":false,"given":"Hiroyuki","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Department of Endocrine Surgery, Kanagawa Cancer Center , Kanagawa 241-8515 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Masudo","sequence":"additional","affiliation":[{"name":"Department of Endocrine Surgery, Kanagawa Cancer Center , Kanagawa 241-8515 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"issue":"1","key":"2024101600041692600_dgae271-B1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","article-title":"Overview of the 2022 WHO classification of thyroid neoplasms","volume":"33","author":"Baloch","year":"2022","journal-title":"Endocr Pathol"},{"issue":"2","key":"2024101600041692600_dgae271-B2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41574-023-00920-6","article-title":"Genomic alterations in thyroid cancer: biological and clinical insights","volume":"20","author":"Landa","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"2024101600041692600_dgae271-B3","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrendo.2014.115","article-title":"Pax-8-PPAR-\u03b3 fusion protein in thyroid carcinoma","volume":"10","author":"Raman","year":"2014","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"2024101600041692600_dgae271-B4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc3431","article-title":"Molecular pathogenesis and mechanisms of thyroid cancer","volume":"13","author":"Xing","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"13","key":"2024101600041692600_dgae271-B5","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","article-title":"Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers","volume":"24","author":"Pozdeyev","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"9940","key":"2024101600041692600_dgae271-B6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"2024101600041692600_dgae271-B7","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"2024101600041692600_dgae271-B8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"2024101600041692600_dgae271-B9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/thy.2014.0123","article-title":"BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer","volume":"25","author":"Falchook","year":"2015","journal-title":"Thyroid"},{"issue":"9","key":"2024101600041692600_dgae271-B10","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"2024101600041692600_dgae271-B11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"2024101600041692600_dgae271-B12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"2024101600041692600_dgae271-B13","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/cas.14754","article-title":"Establishment and implementation of cancer genomic medicine in Japan","volume":"112","author":"Mukai","year":"2021","journal-title":"Cancer Sci"},{"issue":"11","key":"2024101600041692600_dgae271-B14","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1158\/2159-8290.CD-22-0417","article-title":"C-CAT: the national datacenter for cancer genomic medicine in Japan","volume":"12","author":"Kohno","year":"2022","journal-title":"Cancer Discov"},{"issue":"2","key":"2024101600041692600_dgae271-B15","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ng.3774","article-title":"CIVic is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer","volume":"49","author":"Griffith","year":"2017","journal-title":"Nat Genet"},{"issue":"12","key":"2024101600041692600_dgae271-B16","doi-asserted-by":"crossref","first-page":"e1007752","DOI":"10.1371\/journal.pgen.1007752","article-title":"BRCA challenge: BRCA exchange as a global resource for variants in BRCA1 and BRCA2","volume":"14","author":"Cline","year":"2018","journal-title":"PLoS Genet"},{"issue":"D1","key":"2024101600041692600_dgae271-B17","doi-asserted-by":"crossref","first-page":"D835","DOI":"10.1093\/nar\/gkz972","article-title":"ClinVar: improvements to accessing data","volume":"48","author":"Landrum","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"2024101600041692600_dgae271-B18","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"2024101600041692600_dgae271-B19","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: efficient and comprehensive analysis of somatic variants in cancer","volume":"28","author":"Mayakonda","year":"2018","journal-title":"Genome Res"},{"issue":"6","key":"2024101600041692600_dgae271-B20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1507\/endocrj.EJ20-0063","article-title":"BRAF and tert promoter mutations: clinical application in thyroid cancer","volume":"67","author":"Chung","year":"2020","journal-title":"Endocr J"},{"issue":"11","key":"2024101600041692600_dgae271-B21","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/modpathol.2017.75","article-title":"Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation","volume":"30","author":"Oishi","year":"2017","journal-title":"Mod Pathol"},{"issue":"19","key":"2024101600041692600_dgae271-B22","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.1158\/1078-0432.CCR-17-1183","article-title":"Genomic alterations in fatal forms of non-anaplastic thyroid cancer: identification of MED12 and RBM10 as novel thyroid cancer genes associated with tumor virulence","volume":"23","author":"Ibrahimpasic","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2024101600041692600_dgae271-B23","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Invest"},{"issue":"8","key":"2024101600041692600_dgae271-B24","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1158\/1078-0432.CCR-22-2882","article-title":"Genomic and transcriptomic characteristics of metastatic thyroid cancers with exceptional responses to radioactive iodine therapy","volume":"29","author":"Boucai","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2024101600041692600_dgae271-B25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Cell"},{"issue":"12","key":"2024101600041692600_dgae271-B26","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1089\/thy.2019.0802","article-title":"RET, NTRK, ALK, BRAF, and MET fusions in a large cohort of pediatric papillary thyroid carcinomas","volume":"30","author":"Pekova","year":"2020","journal-title":"Thyroid"},{"issue":"9","key":"2024101600041692600_dgae271-B27","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","article-title":"Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019","volume":"6","author":"Maniakas","year":"2020","journal-title":"JAMA Oncol"},{"key":"2024101600041692600_dgae271-B28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ejca.2017.01.013","article-title":"Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid","volume":"75","author":"Tahara","year":"2017","journal-title":"Eur J Cancer"},{"issue":"6","key":"2024101600041692600_dgae271-B29","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1530\/ERC-17-0562","article-title":"Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer","volume":"26","author":"Song","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2024101600041692600_dgae271-B30","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1089\/thy.2016.0350","article-title":"Effects of coexistent BRAF(V600E) and TERT promoter mutations on poor clinical outcomes in papillary thyroid cancer: a meta-analysis","volume":"27","author":"Moon","year":"2017","journal-title":"Thyroid"},{"issue":"2","key":"2024101600041692600_dgae271-B31","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jamaoncol.2016.3288","article-title":"Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality","volume":"3","author":"Liu","year":"2017","journal-title":"JAMA Oncol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae271\/57399185\/dgae271.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/11\/2784\/59765494\/dgae271.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/11\/2784\/59765494\/dgae271.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T20:04:48Z","timestamp":1729022688000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/11\/2784\/7647724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,17]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,4,17]]},"published-print":{"date-parts":[[2024,10,15]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae271","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,4,17]]}}}